ECO Animal Health Group plc
(AIM: EAH)

ECO RECEIVES USA MARKETING AUTHORISATION FOR AIVLOSIN® FOR SWINE RESPIRATORY DISEASE

ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation for Aivlosin® in the United States from the Center for Veterinary Medicine (CVM) of the Food and Drug Administration (FDA).

Aivlosin^®, ECO’s patented antimicrobial, is used for the treatment of a variety of economically important respiratory and enteric (gut) diseases in pigs and poultry.

This authorisation is for the use of Aivlosin® 625 mg/g water soluble granules in for the control of swine respiratory disease (SRD) associated with Bordetella bronchiseptica, Haemophilus parasuis, Pasteurella multocida, and Streptococcus suis, four important bacterial respiratory pathogens of swine.

This new treatment meets all the guidelines for the responsible use of antimicrobials. Importantly, with global concerns about the use of antibiotics in food production animals, this treatment is under the control of veterinarians, is available under prescription only and has a low, highly effective therapeutic dose rate, short treatment duration and a zero day drug withholding period.

The product will be marketed through Pharmgate Animal Health LLC our well-established sales and marketing joint venture formed in 2010 with Pharmgate LLC, the majority-owned U.S. subsidiary of Jinhe Biotechnology Co. Ltd. in China.

Peter Lawrence, Chairman of ECO, commented “We are extremely pleased to receive this second marketing authorisation for the Aivlosin® water soluble granules formulation in the United States. The swine respiratory disease segment is a key one and this latest approval demonstrates ECO’s continued progress to becoming a major force in the international market for veterinary pharmaceutical products.”

This announcement contains inside information.

Contacts:

ECO Animal Health Group plc

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders

View source version on businesswire.com: http://www.businesswire.com/news/home/20170723005030/en/

Copyright Business Wire 2017

• News Channel